All Pediatric MVID Patients Advance to Extension Phase in Jaguar's Pivotal Crofelemer Trial
JAGX is trading near its 52-week low of $0.325 (13% above the low) on elevated volume (3.0× avg).
Summary
Jaguar Health's pivotal crofelemer trial for MVID has cleared a key hurdle: all randomized pediatric patients are moving into the single-blind extension phase after an independent Data Monitoring Committee authorized continued treatment. This keeps the program on track for an NDA filing in mid-2027 for an ultrarare disease with only ~200 patients worldwide. The company also flagged a Phase 2 SBS-IF completion by mid-2027 and ongoing business development talks for non-dilutive funding. Given the company's going concern warning and $3.8M cash, positive clinical progress is critical to its survival and any partnership interest.
At the time of this announcement, JAGX was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.33 to $85.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.